The Extra-Islet Pancreas Supports Autoimmunity in Human Type 1 Diabetes

3

Barlow, G.L.^{1,2,+}, Schürch, C.M^{2,4}, Bhate, S.S.², Phillips, D.², Young, A.^{3,6,7}, Dong, S.^{3,5} Martinez, HA.¹,
 Kaber, G.¹, Nagy, N.¹, Ramachandran S.¹, Meng, J.¹, Korpos E.⁹ Bluestone, J.A.^{+,8}, Nolan, G.P.^{+,2},

- 6 Bollyky, P.L.^{+,‡,1}
- 7

8 + Corresponding Author

- 9 ‡ Lead Contact
- 10

11 Affiliations:

- Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford
 University School of Medicine, Stanford, CA 94305, USA
- 14 2. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
- 15 3. Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA
- Department of Pathology and Neuropathology, University Hospital and Comprehensive
 Cancer Center, Tübingen, Germany
- Sean N. Parker Autoimmune Research Laboratory and Diabetes Center, University of
 California San Francisco, San Francisco, CA, USA
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT
 84112, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84112,
 USA
- 24 8. Sonoma Biotherapeutics, South San Francisco, CA 94080 USA
- Institute of Physiological Chemistry and Pathobiochemistry and Cells-in-Motion Interfaculty
 Center, University of Muenster, Germany
- 27
- 28 Further information and requests for resources and reagents should be directed to and will be
- 29 fulfilled by the lead contact, Paul Bollyky (pbollyky@stanford.edu).
- 30
- 31
- 32
- 33
- 34
- 35

36 Abstract

37 In autoimmune Type 1 diabetes (T1D), immune cells infiltrate and destroy the islets of Langerhans — islands of endocrine tissue dispersed throughout the pancreas. However, the 38 39 contribution of cellular programs outside islets to insulitis is unclear. Here, using CO-Detection 40 by indEXing (CODEX) tissue imaging and cadaveric pancreas samples, we simultaneously examine 41 islet and extra-islet inflammation in human T1D. We identify four sub-states of inflamed islets 42 characterized by the activation profiles of CD8⁺T cells enriched in islets relative to the surrounding 43 tissue. We further find that the extra-islet space of lobules with extensive islet-infiltration differs 44 from the extra-islet space of less infiltrated areas within the same tissue section. Finally, we 45 identify lymphoid structures away from islets enriched in CD45RA⁺ T cells — a population also 46 enriched in one of the inflamed islet sub-states. Together, these data help define the 47 coordination between islets and the extra-islet pancreas in the pathogenesis of human T1D. 48

49

50

- 51 **Keywords**: Type 1 Diabetes; Insulitis; Autoimmunity; Multiplexed Imaging; CODEX; Systems
- 52 Immunology; Tissue Architecture

53 Main

54 In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a 55 process called "insulitis". T1D results in a critical requirement for exogenous insulin and affects 56 over eight million individuals world-wide with an estimated 0.5 million new diagnoses each year¹.

57 Recently, the first immunotherapy for delaying T1D onset, teplizumab (a human anti-CD3 58 monoclonal antibody) was approved by the US Food and Drug Administration². However, this 59 treatment and other immunotherapies help only a small fraction of patients and are significantly 60 less effective after patients progress to overt T1D^{3–9}. A better understanding of T1D pathogenesis

61 is essential to building on this progress.

One of the challenges of studying human T1D pathology is the availability of suitable tissue samples. Obtaining pancreatic biopsies raises the risk of surgical complications and the progressive nature of T1D would necessitate serial, longitudinal studies over time, which is prohibitive¹⁰. Fortunately, the Juvenile Diabetes Research Foundation (JDRF) Network for Pancreatic Organ Donors with Diabetes (nPOD) have provided human pancreatic tissues from cadaveric donors for this study^{11,12}. nPOD has enabled substantial progress towards characterizing the pathology of human T1D^{13–17}.

69 Our understanding of key features of human T1D pathology remains limited. Although the 70 cellular composition of insulitis, inflammation specifically of the islets, has been studied 71 extensively, this has been done in separate studies looking at different tissue sections, prohibiting 72 an understanding of how the numerous cellular programs in insulitis are coordinated throughout 73 disease. This was recently addressed using Imaging Mass Cytometry (IMC), which uncovered 74 alterations in β -cell phenotypes, immune composition, vascular density, and basement 75 membrane that accompany T1D^{18,19}. However, these studies did not deeply phenotype islet-76 infiltrating CD8⁺T cells, believed to be major driver of β -cell elimination.

77 Recently, intriguing differences in the extra-islet spaces of T1D and healthy controls have been 78 reported. First, the abundance of multiple types of immune cells outside islets are increased in T1D patients compared to non-T1D controls^{20–22}. Second, HLA-DR expression is increased on 79 ductal cells in T1D tissue donors, hinting at a functional link with CD4⁺T cells²³. Third, peri-insulitis, 80 81 the accumulation of immune cells outside islets, is observed in tissues from patients with T1D²⁴, 82 indicating that not all T cells enter the pancreas directly via islet microvasculature²⁵. Fourth, in 83 human T1D, but less so in most animal models, islets in different regions of the pancreas are infiltrated at strikingly different rates for reasons that are unknown²⁶. This suggests that the 84 85 extra-islet compartment could be responsible by governing the targeting of islets. Finally, tertiary 86 lymphoid structures (TLS) — dense aggregates of lymphoid cells indicative of local immune 87 activation — are observed outside islets in T1D patients¹⁷.

88 In summary, analyzing both compartments simultaneously could help identify how these extra-

89 islet factors influence islet pathogenesis. However, to date, multiplexed imaging studies have

90 only examined islets. A comprehensive, spatially resolved cellular analysis of both compartments

91 in T1D is lacking.

92 Here, we investigated the islet and extra-islet pancreas together. We used CO-Detection by 93 indexing (CODEX) with an antibody panel targeting 54 antigens to samples from a cohort of T1D 94 patients with insulitis as well as non-T1D individuals with and without islet-specific 95 autoantibodies (AA- and AA+ respectively) obtained through the JDRF nPOD program. We 96 analyzed approximately 2000 islets and broad swaths of the extra-islet tissue to evaluate local 97 and distal spatial architecture. We then used pseudotime analysis to characterize insulitis sub-98 states based on the activation states of islet-infiltrating CD8⁺T cells. We further investigated the 99 cellular changes in niches and lobules beyond islets. Our results implicate both the islet 100 microenvironment and inflammation at distal sites within the pancreas in the progression of 101 insulitis.

102 Cohort curation, image acquisition, and cell annotation

103 The JDRF nPOD is a national registry of cadaveric pancreases donated by T1D patients that has 104 transformed the ability of researchers to investigate the pathways underlying the progression of 105 human T1D^{11,12}. Insulitis is present in only a small fraction of T1D cases, including those available from nPOD^{27,28}. Although nPOD has close to 200 T1D cases, at the time of our study, nPOD had 106 107 only 17 with documented insulitis. Of these, triple-immunohistochemistry for Insulin, Glucagon, 108 and CD3 was performed. T1D and AA+ cases that had CD3+ staining in islet or peri-islet spaces 109 and tissue still available were selected for our study. The final cohort included two AA+ cases, 110 eight T1D cases, and three non-T1D controls. Given that insulitis is not detected in non-T1D cases²⁹, the blocks from controls were selected randomly. The T1D cases varied in the time 111 112 between diagnosis and death from 0 years (diagnosed at death) to 6 years (Figure 1.A, left). The 113 causes of death were mostly unrelated to T1D complications (Supplemental Table 1). Therefore, 114 the time since diagnosis is not a reflection of the aggressiveness of the individual's disease.

Large regions averaging 55 mm² were imaged with CODEX as previously described^{30–32}. Regions 115 were selected to capture islets and the surrounding region simultaneously (Figure 1.A, center 116 117 and right). CellSeg was used to segment cell nuclei and quantify marker expression from CODEX 118 images as previously described³³. In total, our dataset consisted of 7.0x10⁶ cells across all donors (ranging from 3.0x10⁵ to 9.8x10⁵ cells per donor). Twenty-one cell types were identified with 119 120 Leiden clustering and manual merging and visualized using Uniform Manifold Approximation and 121 Projection (UMAP) (Figure 1.B, Supplemental Table 2). Endocrine cells were manually gated from 122 UMAP embeddings derived from Proinsulin, Glucagon, and Somatostatin to identify β-cells, α-123 cells, and δ -cells respectively. Immune cells were sub-clustered with the Leiden algorithm using 124 immune-specific markers (Figure 1.C, Supplemental Table 2). To verify the accuracy of our 125 annotations, we overlaid cell labels onto the original images (Supplemental Figure 1.A). Of note, 126 we could not accurately identify macrophage subsets or distinguish dendritic cells from macrophages due to the panel design, complex combinations of co-expression, and the difficulty 127 128 in segmenting and quantifying markers on myeloid populations due to their morphology. 129 Therefore, we refer to this cluster as "macrophage/DCs" In addition, we identified a cell 130 population that could not be definitively annotated, expressing high levels of CD45, CD69, 131 Granzyme-B, and CD44, intermediate levels of CD16, S100A6, Galectin-3, and Hyaluronan, but 132 not expressing CD3, CD20, CD56, CD57, CD15, or MPO. We confirmed from the raw images that

133 CD3, CD4, and CD8 were not internalized, indicating activation, nor did these cells express other

- 134 T cell activation markers CD45RA, CD45RO, PD-1, or LAG-3 (Figure 1.C, Supplemental Figure 1A,
- bottom right). This population could represent a type of innate lymphoid cell³⁴ and was labeled
- 136 "Granzyme-B⁺/CD3-".

137 Islet- and extra-islet regions are altered in T1D

138 We first sought to identify cellular changes in T1D within islets specifically. Previous reports 139 observed that insulin-containing islets are significantly more common in recent-onset T1D cases than cases with diabetes durations of greater than one year^{27,35,36}. Similarly, we found that 140 141 samples from patients who had been diagnosed with T1D for 0-2 years had significantly reduced 142 β -cell frequencies compared to non-T1D controls. Furthermore, samples from subjects with 143 disease durations of 5-6 years had minimal remaining β -cell mass (Figure 1.D). Whereas one AA+ 144 case had β -cell mass comparable to those of cases with disease duration of 0-2 years, the other 145 AA+ case was comparable to non-T1D controls (Figure 1.D). The total islet area imaged was 146 comparable across all donors (Supplemental Figure 1.B). 147 Next, we investigated how the abundances of non-endocrine cell types inside islets differed

- across donors. We performed Principal Component Analysis (PCA) on the donors using the
- 149 frequencies of non-endocrine cell types located in islets. Donors were clearly separated into two 150 groups by the first two principal components; one group included all T1D cases and one AA+ case
- and the second included all non-T1D cases and the other AA+ case (Figure 1.E). In this analysis,
- 151 and the second included an non-TD cases and the other AA+ case (Figure 1.2). In this analysis, 152 we did not consider β -cells, α -cells, and δ -cells. Thus, donors were stratified by disease duration
- 152 we did not consider p-cens, and o-cens. This, donors were stratmed by disease duration 153 strictly according to the abundances of immune and other pancreatic, non-endocrine cell types
- 154 in the islets.

155 We next considered only cells located outside islets. Again, donors were clearly separable by the

156 first two principal components (Figure 1.F). The first principal component separated cases with

157 times since diagnosis between 0-2 years from non-T1D, AA+, and cases with diabetes durations

- of 5-6 years (Figure 1.F). The second principal component separated cases with diabetes
- 159 durations of 5-6 years from the rest (Figure 1.F). Therefore, both the islet and extra-islet spaces
- 160 of T1D and non-T1D cases were distinct.
- 161 Many cell types were increased in T1D cases with times since diagnosis of 0-2 years relative to 162 non-T1D controls (Supplemental Figure 1C). In T1D cases with times since diagnosis of 5-6 years, 163 the abundance of different cell types either remained higher than non-T1D controls or returned 164 to baseline (Supplemental Figure 1.C). This trend was present in both islet and extra-islet regions. 165 These data demonstrate that the immune activity between the islet and extra-islet 166 compartments are coordinated.

Pseudotemporal reconstruction of islet pathogenesis identifies a conserved trajectory of insulitis

169 In human T1D, β -cell destruction does not occur simultaneously across all islets and even 170 neighboring islets can be at different stages of destruction^{18,26,27}. We therefore used pseudotime

analysis to infer the most likely progression of a single islet through disease space¹⁸. To develop

a pseudotemporal map, we quantified the cellular composition of each islet, including cells within

173 $\,$ 20 μm of the islet's boundary, and applied the pseudotime algorithm PArtition-based Graph

- 174 Abstraction (PAGA)³⁷ (Figure 2.A; Figure 2.B). PAGA was selected because it is a high-performing
- algorithm able to identify multiple trajectories, if they exist, while making minimal assumptions
- 176 about the true structure³⁸.

177 Displayed in Figure 2.B is the PAGA force-directed layout where each point represents an islet. 178 Each islet's color reflects the pseudotemporal distance from the centroid of non-T1D islets. As 179 expected, the islets from different donor groups (no T1D, AA+, T1D) had different distributions 180 across the PAGA map (Figure 2.C). In the PAGA map, a continuum is apparent from islets abundant in insulin-expressing β -cells on the left of the map to islets depleted in β -cells on the 181 182 right (Figure 2.D, Figure 2.E, Figure 2.F, top row). PAGA uses Leiden clustering internally, enabling 183 the following regions of the pseudotime map to be labelled objectively: 1) Islets with low 184 pseudotime values on the left of the map (PAGA-internal Leiden clusters 0 and 5 in Supplemental 185 Figure 2.A) were labelled "Normal" even if they originated from T1D donors. 2) Islets in the 186 middle of the map (PAGA-internal Leiden clusters 6, 2, and 8 in Supplemental Figure 2.A) were 187 elevated in HLA-ABC (MHC Class I) expression, CD8⁺T cells, and macrophage/DCs (Figure 2.D, Figure 2.E, Figure 2.F, rows 2-4) and were labelled "Inflamed". 3) Islets with late pseudotime 188 189 values on the right of the map (PAGA-internal Leiden clusters 1, 3, 7, and 4 in Supplemental Figure 190 2.A) were devoid of β -cells and were labelled "Insulin-Depleted" (Figure 2.D, Figure 2.E, Figure

191 2.F, top row).

192 In addition, islets lacking β-cells occasionally contained CD8⁺T cells and were labelled "Insulin-193 Depleted + Immune Islets" (Figure 2.D, Figure 2.E, Figure 2.F, rows 2-4). The presence of these

islets suggests that signals retaining CD8⁺T cells in islets linger after β -cells die. The distribution

195 of all cell types across pseudotime is reported in Supplemental Figure 2.B.

196 Islets from non-T1D controls and one of the AA+ donors (6314) were primarily in the Normal 197 group to the left of the map (Figure 2.C, Supplemental Figure 2.C). Islets from subjects who had 198 had T1D for of 5-6 years (cases 6195 and 6323) were primarily in the Insulin-Depleted group to 199 the right of the map (Figure 2.C, Supplemental Figure 2.C). Islets from the remaining T1D donors 200 and the other AA+ donor were distributed broadly throughout the map (Figure 2.C,

201 Supplemental Figure 2.C).

We quantified the fraction of each cell type in swaths at varying distances from the islet edge. We found that for B Cells, CD4⁺T cells, CD8⁺T cells, macrophage/DCs, neutrophils, and plasma cells, the fraction of the given cell type in the islet relative to outside the islets increased (Supplemental Figure 2.D), demonstrating that the inflammation in islets was distinct from the inflammation in the extra-islet tissue. Thus, immune cells were targeting islets specifically.

Together, these results illustrate a single, non-branching progression from Normal Islets to Insulin-Depleted Islets via Inflamed Islets, consistent with previous pseudotime analyses¹⁸.

IDO expression on islet vasculature is linked to T cell infiltration

211 We observed islets with vasculature staining positive for indolearnine 2, 3-dioxygenase 1 (IDO). 212 In the tumor microenvironment, IDO is commonly expressed by myeloid cells and suppresses 213 CD8⁺T cell activity through multiple mechanisms, including the induction of FOXP3⁺ regulatory T cells and the inhibition of CD8⁺T cell function³⁹. In islets, IDO co-stained with CD31⁺ vasculature 214 215 but not CD45⁺ immune cells adjacent to vasculature (Figure 2.G). IDO was not expressed by 216 endocrine or other cell types in islets or by vasculature or any cell type outside islets 217 (Supplemental Figure 2.E). We manually quantified vascular expression of IDO on islets 218 throughout pseudotime and found that all but two IDO⁺ islets were in the Inflamed group (Figure 219 2.H). Therefore, IDO expression by islet vasculature was tightly associated with insulitis.

220 A potent inducer of IDO expression is Interferon- γ (IFN- γ), a cytokine highly expressed by 221 activated T cells and macrophages³⁹. Therefore, we hypothesized that IDO expression was 222 induced by infiltrating immune cells during insulitis. We compared the frequency of CD8⁺T cells 223 and macrophage/DCs in islets from the Inflamed group with and without IDO⁺ vasculature and 224 found that CD8⁺T cells were significantly more abundant in islets with IDO⁺ vasculature than islets 225 without IDO+ vasculature (Figure 2.I). In addition, the expression of HLA-ABC, another interferonstimulated gene, was higher in β-cells in IDO+ islets than in β-cells in IDO- islets (Supplemental 226 227 Figure 2.F). However, the abundance of $\gamma\delta$ -T cells and CD4⁺T cells was less strongly associated 228 with IDO+ vasculature and the abundance of macrophage/DCs was not significantly associated 229 with IDO⁺ vasculature (Supplemental Figure 2.F).

In summary, IDO expression by islet vasculature is positively associated with T cell infiltration and
 may be an immunoregulatory checkpoint.

232 Insulitis has sub-states, defined by functional states of

233 CD8⁺T cells

234 CD8⁺T cells are a major component of insulitis (row 4 of Figure 2.E and Figure 2.F) and are capable 235 of directly and indirectly killing β -cells. A comprehensive description of the activation profiles of 236 CD8⁺T cells could provide insight into their roles in T1D pathogenesis. To obtain extremely high-237 quality marker quantification, we trained a neural network on manually labelled images of single 238 T cells (Figure 3.A, Supplemental Figure 3.A). Using our neural network, we quantified the 239 expression of T cell markers on islet CD8⁺T cells (Figure 3.B).

PD-1, TOX, CD45RO, CD69, and CD44—markers of antigen experience—were the markers most frequently expressed by islet-infiltrating CD8⁺T cells (Figure 3.B, Supplemental Figure 3.B). CD8⁺T cells expressing CD45RA (which are either naïve or terminally differentiated effector memory cells (TEMRA)) were detectable in islets, as previously reported¹⁸ (Figure 3.B). In addition, we observed a rare population of CD45RO⁺ CD8⁺T cells co-expressing Lag-3, Granzyme-B, and ICOS (Figure 3.B bottom clade). Lastly, a rare population of CD57⁺ CD8⁺T cells was present but these cells rarely co-expressed LAG-3, Granzyme-B, or ICOS (Figure 3.B top clade). These populations resemble the two exhausted T cell populations identified in the peripheral blood of T1D patients

that were associated with responsiveness to alefacept⁴⁰. Therefore, the activation profiles of islet-infiltrating T cells are heterogeneous.

250 We reasoned that the islet microenvironment may dictate the activation state of CD8⁺T cells by 251 specifically recruiting T cells of a particular state or inducing changes after they enter the islet. If 252 so, islets would contain specific combinations of CD8⁺T cell states. To interrogate this, we 253 performed UMAP only on Inflamed islets, using the frequencies of CD8⁺T cells expressing each 254 functional marker. We identified four inflamed sub-clusters, I-IV, (Figure 3.C top). Here, the term 255 "sub-cluster" is used to highlight that these groups were all contained within the previously 256 defined "Inflamed" cluster and the roman numerals do not imply a temporal ordering. Inflamed-257 I contained only CD8⁺T cells that did not express any of the functional markers analyzed (Figure 258 3.C bottom, top row). Inflamed-II was characterized by a high frequency of CD45RA⁺CD8⁺T cells 259 (Figure 3.C bottom, second row from top and Figure 3.D top row). Inflamed-III was characterized 260 by a low frequency of CD45RA⁺ cells and high frequency of CD45RO⁺ and PD-1⁺ cells (Figure 3.C 261 bottom, third row from top and Figure 3.D middle row). Inflamed-IV was characterized by an enrichment of CD8⁺T cells expressing CD57, LAG-3, ICOS, Granzyme-B, PD-1 or CD45RO (Figure 262 263 3.C bottom, bottom row and Figure 3.D bottom row). In summary, the phenotypes of CD8⁺T cells 264 are coordinated across islets.

Regulation of insulitis sub-states by the islet microenvironment

To identify cellular or molecular factors that regulate the state of CD8⁺T cells in islets, we first inspected the distribution of inflamed sub-clusters in each patient. Each donor possessed islets that belonged to multiple inflamed islet sub-clusters (Figure 3.E). Therefore donor-level factors such as genetics, the location within the pancreas (i.e. head, body, or tail), or time since T1D onset, are not associated. Instead, these insulitis sub-states are conserved among T1D patients.

272 Next, we asked if each T cell marker is enriched in CD8⁺T cells in islets compared to CD8⁺T cells in 273 the peri-islet and exocrine space. We computed the frequencies of each CD8⁺T cell state inside 274 islets of each inflamed sub-cluster and in separate swaths 0-25µm, 25-50µm and 50-100µm away 275 from the islets (Supplemental Figure 3.C). We found that for islets of Inflamed-II, -III, and -IV, 276 functional markers characterizing their CD8⁺T cells were expressed more frequently inside than in the surrounding tissue areas. Although the different functional markers were all enriched on 277 278 islet-infiltrating T cells compared to T cells outside islets, the degree of this enrichment varied 279 across the markers measured (Supplemental Figure 3.C). The markers of Inflamed-IV, LAG-3, 280 ICOS, and Granzyme-B, were highly enriched inside islets (~20% of islet-infiltrating CD8⁺T cells vs 281 <5% of extra-islet CD8⁺T cells). CD45RA and CD69 in Inflamed-II were slightly less enriched in 282 islets (~28% of islet-infiltrating and ~20% of extra-islet CD8⁺T cells). CD45RO and PD-1 in 283 Inflamed-III islets were the most abundant but had the least enrichment in islets (~45% of islet-284 infiltrating CD8⁺T cells vs ~35% of extra-islet CD8⁺T cells) (Supplemental Figure 3.C). This 285 demonstrated that the specific differences in the compositions of CD8⁺T cell states in different 286 islets were attributable to the islet microenvironment and not the surrounding extra-islet spaces.

287 Although macrophage/DCs are abundant in islets from the Inflamed group (Figure 2.E, Figure 288 2.F) and can interact with T cells by presenting antigen or secreting cytokines, neither the 289 expression of markers of macrophage/DC activity nor macrophage/DC abundance was 290 significantly associated with any of the inflamed sub-clusters (Supplemental Figure 3.D). Similarly, 291 no other cell-type nor the vascular expression of IDO was linked to CD8⁺T cell programs in islets 292 (Supplemental Figure 3.D). Accordingly, the four inflamed sub-clusters had identical distributions 293 throughout the original PAGA force-directed layout (Figure 3.F). Therefore, the activation states 294 of islet-infiltrating T cells are independent of the abundance of any of the other cell types we 295 could identify.

Lastly, we compared CD8⁺T cells in islets from the Insulin-Depleted + Immune group to CD8⁺T cells in islets from the Inflamed group. Insulin-Depleted + Immune islets contained a higher frequency of CD45RA+ CD8⁺T cells and a lower frequency of CD45RO+ CD8⁺T cells than Inflamed islets (Figure 3.G). TOX was expressed by a higher frequency of CD8⁺T cells in Insulin-Depleted + Immune islets than CD8⁺T cells in Inflamed islets (Figure 3.G). Importantly, CD45RA+ and TOX were never co-expressed on the same CD8⁺T cell (Figure 3.B). These data indicate that the

302 activation state or persistence of these two populations in islets depends on insulin expression.

303 Vasculature, nerves, and Granzyme-B⁺/CD3- cells 304 outside islets are associated with lobular patterning

305 In the pancreas, islets are grouped within lobules. In some donors, the destruction of islets in T1D 306 exhibits a strong lobular patterning: that is, insulin-positive, immune-infiltrated, and insulin-307 negative islets are each primarily found in different lobules⁴¹. However, other donors are on the 308 other end of this spectrum and have lobules comprised of a random mixture of islets from 309 different stages of pathogenesis.

310 It is unknown why some cases exhibit lobular patterning. One explanation could be an islet-311 intrinsic mechanism where the expression of programs sensitizing beta cells to immune-killing 312 (i.e. stress) are correlated across islets in the same lobule. Alternatively, it could be mediated by 313 cells outside islets if they facilitate extravasation into the lobule or trafficking from one afflicted 314 islet to the next.

315 To systematically investigate lobular patterning in T1D, we used a neural network to segment 316 lobules and assign each single cell and islet to its lobule. We first quantified the degree of lobular 317 patterning within each donor using the intra-class correlation coefficient (ICC). The ICC ranges 318 from 0 to 1 where cases with values closer to 1 have islets whose states are more synchronized 319 within lobules (Figure 4.A). Islets of non-T1D cases and 6314, 6195, and 6323 did not have 320 appreciable variability in their pseudotimes, but in the remaining cases, the ICCs ranged from 321 0.17 to 0.74 (Figure 4.B). This highlights that the magnitude of lobular patterning ranges widely 322 across T1D cases with insulitis.

We employed hierarchical linear modeling (HLM), a statistical framework designed to identify relationships between levels of multi-level data. HLMs are standard in fields where multi-level data are common such as Education, in which students are grouped into classrooms, which are grouped into schools (Gelman et al. 2014) and have been applied in biomedical settings^{43,44}. We

327 were interested in cell-types if their abundance in a lobule correlated with the lobule's average 328 islet pseudotime. Importantly, we omitted the islet region itself from the calculation of a cell 329 type's lobular abundance because we were interested in identifying features in the extra-islet 330 space that were associated with islet destruction. For each cell type, we estimated the effect of 331 its total abundance in a lobule (the number of cells divided by the number of acinar cells to 332 normalize for lobule area) on the pseudotimes of islets in that lobule. We performed this analysis 333 in two-level HLMs for each donor and a three-level HLM considering all donors together (Figure 334 4.C).

335 We identified three cell types — vasculature, nerves, and Granzyme- $B^+/CD3$ - cells — that were 336 significantly associated with lobules across multiple T1D tissue donors. All three were more 337 abundant in lobules with islets late in pseudotime (Figure 4.C boxed rows, Figure 4.D). Samples from cases 6323 and 6195 which had very few insulin-containing islets had increased abundances 338 339 of vasculature, Granzyme-B/CD3- cells, and nerves in their extra-islet spaces compared to non-340 T1D controls (Supplemental Figure 1C), indicating these changes persist through the point when 341 the entire tissue is afflicted. In addition, vasculature, Granzyme-B⁺/CD3- cells, and nerves were 342 increased in Inflamed islets compared to Normal islets indicating that they may serve a role in 343 islets in addition to their role in the extra-islet compartment (Supplemental Figure 4A). Note that 344 Supplemental Figure 4A differs from Supplemental Figure 1C because islets are broken up 345 according to pseudotime, not donor, and not all islets in T1D donors are undergoing insulitis.

Counterintuitively, although CD8⁺T cells and macrophage/DCs were higher in the extra-islet compartments of T1D cases vs non-T1D cases (Supplemental Figure 1C), they were not associated with lobular patterning (they were not more abundant in the extra-islet space of lobules with more advanced insulitis) (Figure 4.C). These data raise the possibility that vasculature, Granzyme-B/CD3- cells, and nerves outside islets help predispose lobules to insulitis or are affected by extensive insulitis.

Immature tertiary lymphoid structures are enriched in subjects with T1D

354 We hypothesized that T cells' interactions with certain cell types in specific areas of the pancreas 355 may be important for their functionality. Therefore, we identified Cellular Neighborhoods (CNs)^{30,45}, tissue regions that are homogeneous and have defined cell-type compositions. To 356 357 identify CNs, single cells were clustered according to the cell-type composition of their twenty 358 nearest spatial neighbors and automatically annotated with the names of enriched cell types 359 (Figure 5.A, See Methods). This resulted in 75 CNs. Throughout the manuscript, CNs are referred 360 to with the nomenclature (Cell Type A|Cell Type B|...) to indicate all the cell types that are 361 enriched in them (See Methods).

- 362 Next, we identified CNs that were more abundant in T1D than non-T1D tissues (Figure 5.B). The
- 363 top three CNs (fold change of abundance in T1D relative to abundance in non-T1D) were (CD8⁺T
- 364 cells | B Cells), (Macrophage | Stromal Cells | B Cells), and (Vasculature | B Cells) (Figure 5.B, Figure
- 365 5.C). We asked whether these three CNs were commonly adjacent to each other as this could
- indicate that they act as components of a larger structure⁴⁵. Measuring the frequency with which

the three B cell CNs were adjacent to each other throughout the tissues demonstrated that the (CD8⁺T cells|B Cells) CN is predominantly found adjacent to both the other CNs but that (Macrophage|Stroma|B Cells) and (Vasculature|B Cells) are less commonly adjacent to each other (Figure 5.D).

We next asked whether these CN assemblies corresponded to either peri-vascular cuffs^{46,47} or tertiary lymphoid structures (TLSs)^{17,46,48}, as these are two B Cell-rich structures commonly present in autoimmune conditions. Although the (CD8⁺T cells | B Cells) CN was adjacent to vessels (Figure 5.D, Figure 5.E), it was not in the perivascular space, as is the case with perivascular cuffs

- (Figure 5.E). In our samples, the (CD8⁺T cells | B Cells) CN did not have segregated T cell and B cell
- 376 zones as seen in mature TLSs, consistent with¹⁷.

377 In summary, the (CD8⁺T cells|B Cells) CN is more abundant in T1D tissues from patients with

- 378 diabetes durations of 0-2 years compared to non-T1D tissues and T1D tissue from patients who 379 had T1D for more than 4 years.

Immature tertiary lymphoid structures are in the extra islet pancreas, and are enriched in CD45RA⁺/CD8⁺T cells

382 We next asked whether the (CD8⁺T cells|B Cells) CN had high endothelial venules (HEV), 383 specialized blood vessels that are commonly found in TLSs that enable naïve lymphocytes to 384 extravasate into peripheral tissues. We observed expression of peripheral lymph node addressin 385 (PNAd), an HEV marker, in the vessels associated with the (CD8⁺T cells|B Cells) CN (Figure 5.E left 386 image) but not in other vessels (data not shown). Although we could not assess the presence of 387 other TLS traits such as follicular dendritic cells, fibroblastic reticular cells, or follicular helper T 388 cells, the aggregation of B cells and presence of HEVs, but the lack of compartmentalized B and 389 T cell zones indicate that instances of the (CD8⁺T cells | B Cells) CN are immature TLSs.

Next, we asked if immature TLSs could support the entry of naïve CD8⁺T cells into the pancreas. We observed CD8⁺T cells co-expressing CD45RA and CD62L (the ligand for PNAd) near PNAd⁺ vasculature (Figure 5.E, middle and right image respectively). Thus, CD45RA⁺/CD8⁺T cells in the pancreas can adhere to HEVs. Furthermore, CD45RA⁺ was enriched three-fold on CD8⁺T cells in the (CD8⁺T cells | B Cells) CN relative to CD8⁺T cells in the tissue as a whole (Figure 5.F), providing additional evidence that CD45RA⁺ T cells may enter the pancreas through HEVs.

We found immature TLS both adjacent (Figure 5.G.1) or not adjacent (Figure 5.G.2) to islets. 396 397 Quantifying the frequency of this adjacency revealed that fewer than half of the immature TLS 398 were adjacent to islets (Figure 5.H). We did not identify any differences in the cellular 399 composition of the immature TLS that were or were not adjacent to islets (Supplemental Figure 400 5A). We reasoned that even if immature TLSs were far from islets, extravasating cells may migrate 401 to islets. Accordingly, islet-adjacent CD45RA⁺ CD8⁺T cells (that were not in islet-adjacent TLSs) co-402 expressed CD62L, suggesting that they originated from the (CD8⁺T cells|B Cell) CN (Figure 5.I). 403 Consistent with this, in one notable tissue donor, regions of the pancreas with Insulin-Depleted 404 islets were enriched in the (CD8⁺T cells|B Cell) CN relative to regions of the pancreas with β -cell 405 containing islets (Figure 5.J). This spatial correlation between the (CD8⁺T cells|B Cells) CN and

406 the destruction of islets implicates immature TLS with islet pathology even if they are not 407 adjacent to islets (Figure 5.J).

408 **Discussion**

409 We have performed CODEX imaging and comprehensive computational analysis of whole 410 cadaveric pancreata from T1D subjects. Our data support several conclusions.

First, our results are consistent with the model previously proposed by Damond et al, who
 proposed a single trajectory for insulitis, characterized by an enrichment in HLA-ABC expression,
 CD8⁺T cells, and macrophage/DCs¹⁸.

414 Second, we are the first to report that IDO+ vasculature is present in inflamed islets but not in 415 normal islets or islets that have lost insulin-expression (Figure 2.G, Figure 2.H). Furthermore, 416 islets with IDO+ vasculature contained higher frequencies of CD8⁺T cells and higher expression of 417 HLA-ABC, but not higher frequencies of macrophage/DCs compared to inflamed islets that did 418 not contain IDO+ vasculature, suggesting that IDO is induced by a cytokine produced by 419 infiltrating CD8⁺T cells such as IFN- γ (Figure 2.I). Given IDO's established tolerogenic role, these 420 data suggest that the loss of IDO on vasculature could be a prerequisite for β -cell death. 421 Leveraging this checkpoint to protect transplanted β -cells from rejection has shown promise⁴⁹ 422 and could be combined with similar approaches using programmed death-ligand 1^{50,51}

We did not observe IDO expression on β-cells, in contrast to Anquetil et al. that report this in healthy patients⁵². Our observations are consistent with data demonstrating that IDO needs to be induced. First, it has been shown with western blot and RT-PCR that human islets require cytokine stimulation to express IDO⁵³. Second, the human protein atlas has tested multiple IDO antibodies and demonstrated that IDO is negative in human islets via immunohistochemistry: (https://www.proteinatlas.org). In addition, the human protein atlas's single-cell RNAseq atlas only report IDO transcripts in immune cells in healthy pancreas.

- Third, we performed the first high-dimensional spatial phenotyping of CD8⁺T cells in T1D islets.
 We found that most T cells were antigen experienced. A small population expressed CD45RA and
 CD69, which could be naïve, TEMRA, or Tscm cells (Figure 3.B). Another population expressed
 Lag-3, Granzyme-B, and ICOS. It is notable that only a small population of islets had Granzyme-Bexpressing T cells. This could indicate that alternative mechanisms are contributing to the
 elimination of β-cells.
- 436 Fourth, the insulitis trajectory is comprised of four sub-clusters, each characterized by the 437 activation profile of the islet-infiltrating CD8+T cells (Figure 3.C). Multiple of these inflamed sub-438 clusters were present in all T1D donors. One potential explanation for this observation is that 439 sub-clusters are capable of inter-converting (Figure 3.E). The factors that regulate the conversion 440 of a given islet between sub-clusters could correspond to immunoregulatory checkpoints that 441 are critical to the progression of T1D. Unfortunately, our search for such features failed to 442 generate any candidates (Supplemental Figure 3.D). By phenotyping T cells at different distances 443 from the islet edge, we were able to determine that the T cell activation profiles characterizing 444 each sub-cluster were only present in the islet, not in the surrounding tissue (Supplemental 445 Figure 3.C). Unfortunately, from our data, we cannot speculate whether the insulitis sub-clusters

arose due to differential stimulation of T cells that had already entered islets, differentialrecruitment of pre-activated T cells, or both.

448 Fifth, pancreatic lobules affected by insulitis are characterized by distinct tissue markers. We 449 discovered that lobules enriched in β -cell-depleted islets were also enriched in nerves, 450 vasculature, and Granzyme- $B^+/CD3$ - cells, suggesting these factors may make lobules permissive to disease (Figure 4.C). The role of islet enervation in T1D has been studied but such work has 451 452 focused on nerves in the islet rather than on nerves in the exocrine tissue⁵⁴. The Granzyme-453 B+/CD3- cells could be natural killer cells; if so, they are most likely of the CD56dim subset as 454 CD56 was not detected on these cells. It is noteworthy that the cell types linked with direct islet 455 invasion were distinct from those linked to lobule patterning even though both sets of cell types 456 were found across islet and extra-islet regions. Therefore, for insulitis to consume every islet, 457 crosstalk may be required between the cell types in the islet and extra-islet compartments. 458 Conversely, inhibiting this interaction might contain pathology to isolated lesions.

Finally, we identify immature TLS away from islets where CD45RA⁺ CD8⁺T cells aggregate. We also observed an inflamed islet-subcluster characterized by an abundance of CD45RA⁺/CD8⁺ T cells. It will be important to determine whether the CD45RA⁺ T cells localized around islets may have originated from immature TLS. In mice, blocking immune egress from lymph nodes reduced

463 the size of TLSs and halted diabetes⁵⁵. Thus, therapeutic targeting of immune cell trafficking to

403 the size of TLSs and halled diabetes²⁴. Thus, therapeutic targeting of infindine cell tranicking to 464. TLS could hole mitigate autoimmunity in human T1D.

- 464 TLS could help mitigate autoimmunity in human T1D.
- 465 Together, these data illuminate relationships between insulitis, the local islet microenvironment466 and inflammation at distal sites.
- 467 A major limitation for the study is the cohort size. Cases with documented insulitis are very rare, significantly limiting the feasibility of curating large cohorts³⁵. Due to this limitation, factors such 468 469 as the donors' histories of drug use, durations of stay in the intensive care unit, and BMIs could 470 not be balanced or statistically adjusted for but should be considered as they may affect exocrine 471 inflammation but not the prevalence of insulitis^{29,56}. In addition, only one of the AA+ cases, Case 472 6267, had detectable insulitis (Figure 2.C). The other case, 6314 tested positive for only one 473 autoantibody, GADA+, and therefore had a significantly lower probability of progressing to overt 474 T1D⁵⁷. Age and diabetes duration are also important criteria to consider when interpreting key
- 475 results (Supplemental Figure 5B-C).
- Another limitation is our limited perspective on myeloid cell populations. Although antibodies in
 our panel detect numerous myeloid markers, we failed to identify any heterogeneity in myeloid
 populations during insulitis. This was likely due in part to the difficulty of segmenting myeloid
 cells and quantifying marker expression due to their morphology. Spatial transcriptomics could
 be used in future studies to better define the myeloid populations and inform additions to future
 CODEX panels.
- 482 Lastly, our samples are 2-dimensional sections which could affect some of the adjacency483 relations.

In conclusion, using a data-driven approach, we mapped conserved sub-states of insulitis and
 integrated the spatial pathology of islet and extra-islet regions into a single model of T1D
 pathogenesis. The tools and computational pipelines developed here will enable further

investigation of immune pathology at the tissue scale that may lead to development of therapiesfor T1D.

489

490 Methods

491 Human tissues

492 Cadaveric pancreatic FFPE tissue sections were obtained through the nPOD program, sponsored 493 by the Juvenile Diabetes Research Fund. Case numbers cited herein are assigned by nPOD and 494 comparable across nPOD-supported projects. 17 cases in the nPOD biorepository had been 495 previously documented to contain insulitis. For each of these 17 cases, we examined the triple 496 stained immunohistochemistry images (CD3, Insulin, and Glucagon) using nPOD's online 497 pathology database to select blocks in which insulitis was present. To ensure that the tissue 498 regions still contained insulitis (and had not been sectioned extensively after their images were 499 uploaded to the nPOD pathology database), we re-sectioned and visualized CD3, Insulin, and 500 Glucagon. The use of cadaveric human tissue samples is approved by Stanford University's 501 Institutional Review Board.

502

503 CODEX data collection

504 CODEX Antibody Generation and Validation. Oligonucleotides were conjugated to purified. 505 carrier-free, commercially available antibodies as previously described^{30,58}. For validation 506 experiments, human tonsils and non-diabetic pancreata were co-embedded in FFPE blocks so 507 both tissues could be stained and imaged simultaneously. Each antibody in the CODEX panel was 508 validated by co-staining with previously established antibodies targeting positive and negative 509 control cell types. Once validated, the concentration and imaging exposure time of each antibody 510 were optimized. The tissue staining patterning was compared to the online database, The Human 511 Protein Atlas, and the published literature. The specificity, sensitivity, and reproducibility of CODEX staining has been previously validated^{30,31,58–60} 512

513

514 CODEX Staining. Staining and imaging was conducted as previously described^{30,58–60}. Briefly, FFPE 515 tissues were deparaffinized and rehydrated. Heat-induced epitope retrieval (HIER) antigen 516 retrieval was conducted in Tris/EDTA buffer at pH9 (Dako) at 97°C for 10 minutes. Tissues were 517 blocked for 1 hour with rat and mouse Ig, salmon-sperm DNA, and a mixture of the non-518 fluorescent DNA oligo sequences used as CODEX barcodes. Tissues were stained with the 519 antibody cocktail in a sealed humidity chamber overnight at 4°C with shaking. The next day, 520 tissues were washed, fixed with 1.6% paraformaldehyde, 100% methanol, and BS3 (Thermo 521 Fisher Scientific), and mounted to a custom-made acrylic plate attached to the microscope.

522

523 *CODEX Imaging.* Imaging was conducted using the Keyence BZ-X710 fluorescence microscope 524 with a CFI Plan Apo λ 20x/0.75 objective (Nikon). "High resolution" mode was selected in Keyence 525 Navigator software, resulting in a final resolution of .37744 µm/pixel. The exposure times are 526 listed in Supplemental Table 3. Regions for imaging were selected by rendering HLA-ABC, 527 Proinsulin, and CD8 and selecting large regions (averaging 55mm²). The full antibody panel and

528 cycle-ordering is detailed in (Supplemental Tables 3 and 4). Biotinylated hyaluronan-binding 529 protein was rendered by adding streptavidin-PE at 1:500 concentration to the 96 well plate 530 containing fluorescent oligos in the last cycle and running the CODEX program normally. DRAQ5 531 was added to the last cycle because we found it stained nuclei more evenly than HOECHST which 532 slightly improved segmentation. Each tissue took between 3 and 7 days to image depending on 533 the tissue area.

534

535 *Characterization of Tertiary Lymphoid Structures.* A serial section from case 6228 was imaged in 536 a separate CODEX experiment using an antibody panel tailored for characterizing tertiary 537 lymphoid structures, as described in Supplemental Table 3. These data were acquired and 538 analyzed identically to the main dataset.

539

540 Image Pre-processing. Drift compensation, deconvolution, z-plane selection was performed using

the CODEX Toolkit uploader (github.com/nolanlab/CODEX)). Cell segmentation using the DRAQ5

542 nuclear channel and lateral bleed compensation was performed with CellSeg³³.

543

544 Cell Type Clustering and Annotation

545 Marker expression was z-normalized within each donor and subsequently clustered in two steps. 546 First, cells were projected into 2 dimensions using the markers indicated in Supplemental Table 2 and Parametric Uniform Manifold Approximation and Projection (pUMAP)⁶² was applied on a 547 548 downsampled dataset. The fit model was used to transform the remaining cells. Cell types were 549 gated using Leiden clustering and manual merging. The cluster containing immune cells was sub-550 clustered using the markers detailed in Supplemental Table 2. Acinar cells contaminating the 551 Immune cluster were gated out and merged with the Acinar cluster from the previous step. The 552 Endocrine class was sub-clustered into α -, β -, and δ -Cells using Glucagon, Proinsulin, and 553 Somatostatin respectively. Clusters were annotated according the heatmap marker expression, 554 and overlaying annotations onto raw images (Supplemental Figure 1.A) using custom scripts in 555 Fiji.

556

557 Islet Segmentation and Pseudotime

558 *Preprocessing.* Windows consisting of the twenty nearest spatial neighbors surrounding each 559 single cell were clustered according to their cell-type composition using Mini Batch K Means with 560 k=200. For this analysis, α -, β -, and δ -Cells were combined into one 'Endocrine' cell type. One 561 cluster was highly enriched in Endocrine cells and accurately defined the islet area. Individual 562 islets were identified using the connected components algorithm and filtering out islets that had 563 fewer than ten total cells.

564

565 *PAGA Analysis.* For each islet, the number of each cell type inside the islet and between the islet 566 edge and 20μm beyond were extracted. To adjust for variation due to the islet size, the cell type 567 counts were divided by the number of endocrine cells inside the islet. Data were then log-568 transformed. The PAGA embedding was computed using the default parameters except for the 569 following: The neighborhood search was performed using cosine distance and 15 nearest 570 neighbors; Leiden clustering used a resolution of 1. For computing the pseudotime values (used 571 in the colormap in Figure 2B, the x-axis in Figure 2F, and Figure 4), the path through the inflamed

- 572 islet was isolated by temporarily omitting 25 islets positioned in the middle of the map between
- 573 Normal and Insulin-Depleted islets. Only 9 of these were from T1D or AA+ donors.
- 574

575 Quantification and Validation of Functional Marker Gating

- 576 Annotation of Ground-Truth Dataset. 4000 CD8⁺T cells were labelled for fifteen markers by an 577 immunologist familiar with the staining patterns of each marker using VGG Image annotator⁶³.
- 578

579 *Automated Thresholding.* For each functional marker of interest, the lateral-bleed-compensated 580 mean fluorescence³³ of cell types known to not express the marker in question were used to 581 calculate a background distribution. Marker-positive cells were defined as those whose 582 expression was greater than the 99th percentile of the background distribution.

583

584 Gating with Neural Network: 22µm x 22µm cropped images of each single cell were used as 585 training data. The marker that the image corresponded to was not included as an input in the 586 neural network and one classifier was trained for all markers. Cells were split into training, 587 validation, and test splits (60/15/25 respectively). ResNet50 architecture and initial weights were 588 imported from the Keras library pre trained on ImageNet. Image augmentation consisted of 589 random flips, rotations, zooms, contrast, and translation (+/- ten pixels only). All weights were 590 unfrozen, and the model was trained for 100 epochs (see accompanying source code for training 591 details).

592

593 Sub-clustering of Inflamed Islets with Cell-Type specific Functional

594 Markers

595 For each Inflamed Islet (n=351), the frequency of each marker expressed by CD8⁺T cells was 596 computed. Single cells inside the islet and within 20 μ m from the islet's edge were combined 597 before the frequency was measured. The subsequent matrix underwent z-normalization 598 followed by UMAP gating using Bokeh. Insulin-Depleted + Immune Islets were defined as islets 599 without β -cells with greater than two CD8⁺T cells and greater than seven macrophage/DCs. These 500 thresholds correspond to the 95th percentiles of CD8⁺T cells and macrophage/DCs in Normal 501 islets.

602

603 Identification of Cellular Neighborhoods

604 Previously, CNs³⁰ were identified by, for each single cell, defining its 'window' as the 20 spatial nearest neighbors. Cells were clustered according to the number of each cell type in their 605 windows using Mini Batch K-Means. The output clusters corresponded to CNs. To ensure our 606 607 method was sensitive to rare neighborhoods, we adapted this algorithm by intentionally over-608 clustering, using k=200 in the K- Means step rather than using a k ranging from 10-20 as used 609 elsewhere^{31,45,64}. Next, to determine which cell types were characteristic of each cluster, we 610 identified, for each cluster, the set of cell-types that were present in more than 80% of the 611 windows allocated to that cluster. We named the clusters according to this set of cell-types and 612 merged all clusters with the same name, resulting in seventy-five CNs. Acinar cells and epithelial

- 613 cells were used in the kNN graph and in the clustering but were not considered when merging
- 614 clusters. Note that this method does not differentiate neighborhoods that have the same 615 combination of cell types but different stoichiometries.

616 Lobule Segmentation

- 617 A training dataset was generated by manually tracing the edges of lobules in ImageJ using the
- 618 ROI function. The ROI were then floodfilled in Python and used as masks for training. For each
- tile, the blank cycle was selected to distinguish tissue from background coverslip. A U-Net
- 620 model was trained for 10 epochs (see attached source code for training details). After stitching
- together all masks, the resulting images required slight refinement where lobules were not
- 622 completely separated, and this was done manually in ImageJ. The connected components in the
- 623 stitched image defined the lobule instances. Cells were assigned to a lobule by indexing the
- 624 lobule mask with their X and Y coordinates. Cells in the inter-lobular space were assigned to
- one "edge" lobule. This resulted in 464 lobules.
- 626

627 Formulation of Hierarchical Linear Models

- 628 For each lobule, the number of each cell type in the extra-islet space was divided by the
- number of acinar cells in the extra-islet space. For all HLMs, the *lme4* package for R was used⁶⁵
- 630 and statistical significance was computed using the *ImerTest* package for R⁶⁶. Lobular cell-type
- abundance was z-normalized within each donor and the pseudotime was z-normalized across
- 632 the entire dataset prior to fitting.
- 633

The ICC was computed using the model: *pseudotime*_{islet} ~ 1 /lobuleID with the *performance* package in R. A value of 0 indicates that the variation in pseudotimes of islets within the same lobule is equal to the variation across all islets in the donor and a value of 1 indicates that the variation in pseudotimes of islets within the same lobule is much smaller than that of all islets in the donor.

- 639
- 640 For each cell type, a two-level, random intercept HLM within each donor was constructed with
- 641 the following formulation (in R formula syntax): *pseudotime*_{islet} ~ *celltype*_{lobule} + (1|lobuleID) and
- 642 a three-level random intercept, random slope HLM including islets from all donors was
- 643 formulated: *pseudotime*_{islet} ~*celltype*_{lobule} +(1+*celltype*_{lobule}/donorID)+(1|lobuleID). Here,
- 644 *pseudotime*_{islet} equals the pseudotime of each islet, *celltype*_{lobule} equals the number of the given
- 645 cell type in a particular lobule divided by the number of acinar cells in that lobule, z-normalized
- 646 within each donor, and *lobuleID* and *donorID* are categorical variables specifying the lobule and
- 647 donor that the given islet belongs to.
- 648

649 Neighborhood Adjacency

- 650 The adjacency between neighborhoods was computed as in⁴⁵. The only modification was that
- 651 neighborhood instances were identified using connected components of the k-NN graph with k=5
- 652 rather than from the thresholded images.

653 Data Availability

- 654 Processed single cell dataframes are accessible at:
- 655
- 656 https://www.dropbox.com/sh/8sqef3iwjb6f4wp/AAAQzFgDOgMBiWh9Jqcb81U8a?dl=0.
- 657
- The raw and stitched, processed data is hosted by the BioImage Archive
- 659 (https://www.ebi.ac.uk/bioimage-archive/) with the accession number
- 660 S-BIAD859.

661 **Code Availability**

- 662 All primary code is attached with the supplementary information and will be posted on the Nolan
- Lab's github upon acceptance. The code is completely open source. The code is not intended as
- a software tool and so no small example data set is applicable.
- 665

666



Figure 1 Profiling T1D pancreata with CODEX high-parameter imaging reveals alterations in the cellular composition of islet and extra-islet compartments.

669 Figure 1.A Left: Schematic of the workflow for selection of nPOD cases. Blues, greens, and reds

indicate non-T1D, AA+, or T1D status, respectively. Center: Schematic for acquisition and
 processing of CODEX highly multiplexed imaging dataset. Right: Schematic of islet and extra-islet

672 pancreatic regions.

Figure 1.B UMAP and Leiden clustering of major cell types. Colors match those in the heatmap

674 shown to the right. Heatmap of mean z-normalized marker expression in each cell-type cluster. 675 Only a subset of the markers used for the UMAP are included in the heatmap to facilitate

676 visualization. A full description of the markers used for the clustering stages is available in

677 Supplemental Table 2.

678 Figure 1.C UMAP of the immune population identified in Figure 1B further clustered using

additional immune markers as described in Supplemental Table 2. Colors match those in heatmap

shown in the heatmap to the right. The heatmap is generated in an identical manner as the

681 heatmap in Figure 1B.

682 Figure 1.D Frequency of β -Cells per donor determined by dividing the number of β -cells by the

total number of β-cells, α-cells, and δ-Cells. Blues, greens, and reds indicate non-T1D, AA+, or T1D status, respectively. Significance was determined using the t-test (* p<0.05, ** p<0.01, *** p<0.001)

Figure 1.E Principal component analysis of the islet compartment. The number of cells of each cell type (omitting α -, β-, and δ -cells) were divided by the number of endocrine cells to adjust for

688 different islet areas. Blues, greens, and reds indicate non-T1D, AA+, or T1D status, respectively.

689 Figure 1.F Principal component analysis of the extra-islet compartment. The number of cells of

690 each cell type (omitting α-, β-, and δ-cells) were divided by the number of acinar cells to adjust

691 for different areas imaged. Blues, greens, and reds indicate non-T1D, AA+, or T1D status,

692 respectively.

693





694 Figure 2 Pseudotemporal reconstruction of insulitis identifies IDO on islet vasculature.

695 Figure 2.A Schematic of islet segmentation and quantification of islet cellular composition.

Figure 2.B PAGA-force directed layout of islets colored by pseudotime. The start point of pseudotime was calculated as the centroid of the non-T1D islets. Representative islets from different stages of pseudotime are indicated with black points and their raw images are depicted in Figure 2.D. Normal, Inflamed, and Insulin-Depleted groups were obtained by merging the clusters output by the PAGA algorithm (Supplemental Figure 2.A).

- Figure 2.C Islet distribution across pseudotime for each donor. The titles indicate nPOD case IDs as in Supplemental Table 1. The frequency of islets from each donor in each stage of islet pseudotime is reported in Supplemental Figure 2.C.
- Figure 2.D Images of Proinsulin, HLA-ABC, CD163, and CD8 staining in islets representative of
 different points along pseudotime as indicated in B. Scale bars (lower left of each column)
 indicate 100μm.
- Figure 2.E Quantification of selected features across pseudotime overlaid onto the PAGA forcedirected layout. For β -cells, macrophage/DCs, and CD8⁺T cells, the values correspond to log(# cells/# endocrine cells). For HLA-ABC, the mean HLA-ABC expression for each cell in the islet was computed and log transformed.
- 711Figure 2.F Quantification of selected features across pseudotime. For β-cells, macrophage/DCs,712and CD8⁺T cells, the values correspond to log(# cells/# endocrine cells). For HLA-ABC, the mean
- 713 HLA-ABC expression for each cell in the islet was computed and log transformed. Color legend:
- 714 Normal islets: pink; Inflamed islets: brown; Insulin-Depleted islets: purple. Black points
- 715 demarcate LOWESS regression.
- 716 Figure 2.G Representative image of an islet from the Inflamed group stained with IDO and, from
- 717 left to right, Synaptophysin, CD31, and CD45. Arrows indicate IDO⁺/CD31⁺ vasculature. Right 718 shows that IDO⁺ cells are negative for CD45 and therefore, are not immune cells associated with
- vasculature. Scale bar (bottom left image) indicates 50 μm.
- 720 Figure 2.H Distribution of IDO expression on islet vasculature across pseudotime.
- 721 Figure 2.I Association of IDO⁺ islet vasculature with islet CD8⁺T cell density. The y-axis corresponds 722 to the number of CD8⁺T cells per endocrine cell per islet. CD8⁺T cell counts were normalized to 723 adjust for islet size. The x-axis indicates whether islets contain IDO⁺ vasculature. Each color 724 corresponds to a donor. All donors with detectable IDO⁺ islet vasculature are displayed: 6480, 725 6267, 6520, 6228, and 6362. Colors are same as in Figure 2.C. IDO⁺ vasculature was manually 726 quantified. For combined donors, significance was determined with a mixed-effect linear model, 727 p = 1.5 x 10-12 (Satterthwaites's method ImerTest R package). The complete breakdown per 728 donor is reported in Supplemental Figure 2.F.
- 729



730 Figure 3 Insulitis has sub-states, characterized by CD8⁺T cell functionality

- 731 Figure 3.A Schematic of marker-quantification with a ResNet50 neural network. Raw images are
- input, and the neural network outputs a number between 0 and 1 indicative of the level of
- confidence that the cell expresses that marker with 1 indicating the highest confidence.
- Figure 3.B Heatmap of all 2,855 Inflamed Islet CD8⁺T cells, hierarchically clustered according to
 marker expression predicted by the neural network.
- 736 Figure 3.C Top) UMAP of Inflamed Islets based on frequencies of markers on CD8⁺T cells in islets.
- 737 Bottom) Mean frequencies of each marker on CD8⁺T cells in islets of each inflamed sub-cluster.
- Figure 3.D Representative images of islets from each subcluster with associated immune markers.
 Scale bars indicate 50 μm.
- Figure 3.E Frequencies of islets from each subcluster per donor in AA+ and T1D samples. Colorindicates subcluster as in panel C.
- Figure 3.F Distribution of the islets of Inflamed-I through -IV on the PAGA force-directed layoutshown in Figure 2.B
- Figure 3.G Differences in marker expression frequencies between CD8⁺T cells in islets from the Inflamed group and from the Insulin-Depleted + Immune group. T cells from all islets of the specified groups were pooled within each donor to compute the frequencies of marker expression. Significance was determined using the Wilcoxon signed-rank test (* p<0.05, ** p<0.01, *** p<0.001) and was not corrected for multiple hypothesis testing.

749



Figure 4 Vasculature, nerves, and Granzyme-B⁺/CD3- cells in the extra-islet pancreas are associated with the lobular patterning of islet pathogenesis

752 Figure 4.A A schematic of the method for quantifying lobular patterning of insulitis. Lobules were

753 segmented and colored accordingly. The islets are colored according to their composition of b-

cells and a-cells. Top: A region from case 6228 with a strong lobular grouping effect and an ICC

closer to 1. Bottom: A region from case 6267 with a weak lobular grouping effect and an ICCcloser to 0.

757 Figure 4.B Lobular patterning of insulitis within each donor. Each point represents an islet. The x-

axis represents the islet pseudotime. The y-axis is ordinal, representing the rank of each lobule according to the mean pseudotime of its islets. Violin plots per lobule are overlaid. Abbreviations:

- 760 ICC: Intraclass correlation coefficient.
- 761 Figure 4.C Cell types associated with lobular patterning. Top: Schematic of the hierarchical linear
- 762 model. Cells in islets were omitted when computing the lobular abundance of each cell-type.
- 763 Bottom: Coefficients of two-level models trained on each donor separately (columns labeled by
- donor) and a three-level model (right column). Color corresponds to the coefficient and features
- 765 with p>0.05 are white. Significance was determined using Satterthwaites's method in the
- 766 ImerTest R package. No adjustment for multiple hypothesis testing was applied.

Figure 4.D Visualization of vasculature (top), Granzyme-B/CD3- cells (middle), and nerves (bottom) in two lobules. The left lobule represents lobules with islets earlier in pseudotime and a lower abundance of the given cell type in the lobule. The right lobule represents lobules with islets late in pseudotime and a greater abundance of the given cell type in the lobule.

771



βCells ^{LOW} CN ^{HIGH}

CN LOW

Figure 5 Immature tertiary lymphoid structures far from islets are potential staging areas for islet-destined CD8⁺T cells

774 Figure 5.A Schematic of algorithm for identifying CNs. Red point indicates index cell for the CN.

- 775 Orange points indicate the nearest neighbors of the index cell. Windows are collected for each
- cell in the dataset (indicated by orange arrows).

Figure 5.B Cell-type compositions of the top CNs organized in decreasing order of the fold increase in abundance in T1D vs. non-T1D samples. Each column in the heatmap indicates the mean density of that cell type in the 20 nearest spatial neighbors of cells assigned to the CN designated for that row. CN abundance was calculated as the number of cells assigned to the given CN divided by the number of acinar cells. Abbreviations: Vasc.: vasculature; Mac.: macrophage/DCs; Lym.: lymphatics. Neu.: neutrophils; CD8 T: CD8⁺T cells; CD4 T: CD4⁺T cells. Endocrine cell types were merged during CN annotation and are labeled "Islet".

- Figure 5.C Mean abundances of the CD8⁺T cell and B cell CNs per donor. Abundance was calculated as the number of cells assigned to the given CN divided by the number of acinar cells. Significance was determined using the Mann-Whitney U test (* p<0.05,** p<0.01, *** p<0.001).
- 787 No adjustment for multiple hypothesis testing was applied.

Figure 5.D Top: Adjacency frequencies of (CD8⁺T cells| B Cell CN) with (Macrophage|Stroma|B Cells) and (Vasculature| B Cells) CNs. The adjacency frequency was calculated as the number of instances of the source CN adjacent to the destination CN divided by the total number of instances of the source CN. Bottom Left: Raw image of a representative assembly of the three CNs (CD8⁺T cells| B Cell CN), (Macrophage|Stroma|B Cells), and (Vasculature| B Cells) displaying CD8 and CD20 staining. Bottom Right: The same assembly as to the left colored by CN. Scale bar indicates 50µm).

- Figure 5.E Representative images of co-localization of PNAd⁺ endothelium and CD45RA⁺ CD62L⁺
 CD8⁺T cells located in the (CD8⁺T cells|B Cells) CN. Scale bar indicates 50µm.
- Figure 5.F Frequency of CD45RA expression on CD8⁺T cells located in (CD8⁺T cell | B cell) CN relative to CD8⁺T cells throughout the tissue. Significance was determined with a Wilcoxon signed-rank test (* p<0.05, ** p<0.01, *** p<0.001).
- Figure 5.G Representative images of (CD8⁺T cells|B Cells) instances adjacent to islets (G.1) and
 not adjacent to islets (G.2). Scale bars indicate 200μm.
- Figure 5.H Quantification of the adjacency frequencies between the (CD8⁺T cells|B Cells) CN and
 CNs rich in endocrine cells (i.e "Islet CNs"). Mean, std: mean and standard deviation adjacency
 frequency across T1D donors. Abbreviations: Vasc.: vasculature; Mac.: macrophage.
- 805 Figure 5.I Representative images of islet-adjacent CD45RA⁺ CD62L⁺ CD8+T cells. Scale bar 806 indicates 50 μ m.
- Figure 5.J Image showing the spatial distribution of the (CD8⁺T cells|B cells) CN instances relative to islets and the enrichment of (CD8⁺T cells|B cells) CN instances in areas of the pancreas with islets lacking β -Cells.

810 References

- Gregory, G. A. *et al.* Global incidence, prevalence, and mortality of type 1 diabetes in 2021
 with projection to 2040: a modelling study. *Lancet Diabetes Endocrinol.* 10, 741–760
 (2022).
- 814
 2. Hirsch, J. S. FDA approves teplizumab: a milestone in type 1 diabetes. *Lancet Diabetes*815 *Endocrinol.* 11, 18 (2023).
- 816 3. Herold, K. C. *et al.* Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses
 817 in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic
 818 and Immunologic Features at Baseline Identify a Subgroup of Responders. *Diabetes* 62,
 819 3766–3774 (2013).
- 4. Perdigoto, A. L. *et al.* Treatment of type 1 diabetes with teplizumab: clinical and
 immunological follow-up after 7 years from diagnosis. *Diabetologia* 62, 655–664 (2019).
- 822 5. Herold, K. C. *et al.* An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1
 823 Diabetes. *N. Engl. J. Med.* 381, 603–613 (2019).
- 824 6. Pescovitz, M. D. *et al.* Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell
 825 Function. *N. Engl. J. Med.* 361, 2143–2152 (2009).
- 826 7. Orban, T. *et al.* Co-stimulation modulation with abatacept in patients with recent-onset type
 827 1 diabetes: a randomised, double-blind, placebo-controlled trial. *Lancet Lond. Engl.* 378,
 828 412–419 (2011).
- 8. Orban, T. *et al.* Costimulation Modulation With Abatacept in Patients With Recent-Onset
 Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. *Diabetes Care* 37, 1069–
 1075 (2014).
- 832 9. Bluestone, J. A., Buckner, J. H. & Herold, K. C. Immunotherapy: Building a bridge to a cure
 833 for type 1 diabetes. *Science* 373, 510–516 (2021).
- 10. Krogvold, L. *et al.* Pancreatic biopsy by minimal tail resection in live adult patients at the
 onset of type 1 diabetes: experiences from the DiViD study. *Diabetologia* 57, 841–843
 (2014).
- 11. Campbell-Thompson, M. *et al.* Network for Pancreatic Organ Donors with Diabetes (nPOD):
 Developing a Tissue Biobank for Type 1 Diabetes. *Diabetes Metab. Res. Rev.* 28, 608–617
 (2012).
- Pugliese, A. *et al.* The Juvenile Diabetes Research Foundation Network for Pancreatic Organ
 Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. *Pediatr. Diabetes* 15, 1–9 (2014).
- 843 13. Wilcox, N. S., Rui, J., Hebrok, M. & Herold, K. C. Life and death of β cells in Type 1
 844 diabetes: a comprehensive review. *J. Autoimmun.* **71**, 51–58 (2016).
- 845 14. Arif, S. *et al.* Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1
 846 Diabetes. *Diabetes* 63, 3835–3845 (2014).
- 847 15. Leete, P. *et al.* Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and
 848 the Age at Onset of Type 1 Diabetes. *Diabetes* 65, 1362–1369 (2016).
- 849 16. Martino, L. *et al.* Mast cells infiltrate pancreatic islets in human type 1 diabetes.
 850 *Diabetologia* 58, 2554–2562 (2015).
- 17. Korpos, É. *et al.* Identification and characterisation of tertiary lymphoid organs in human
 type 1 diabetes. *Diabetologia* 64, 1626–1641 (2021).
- 18. Damond, N. *et al.* A Map of Human Type 1 Diabetes Progression by Imaging Mass
 Cytometry. *Cell Metab.* 29, 755-768.e5 (2019).

- Wang, Y. J. *et al.* Multiplexed In Situ Imaging Mass Cytometry Analysis of the Human
 Endocrine Pancreas and Immune System in Type 1 Diabetes. *Cell Metab.* 29, 769-783.e4
 (2019).
- 858 20. Rodriguez-Calvo, T., Ekwall, O., Amirian, N., Zapardiel-Gonzalo, J. & von Herrath, M. G.
 859 Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the
 860 Pathogenesis of Type 1 Diabetes. *Diabetes* 63, 3880–3890 (2014).
- 21. Campbell-Thompson, M., Rodriguez-Calvo, T. & Battaglia, M. Abnormalities of the
 Exocrine Pancreas in Type 1 Diabetes. *Curr. Diab. Rep.* 15, 79 (2015).
- 863 22. Bender, C., Rodriguez-Calvo, T., Amirian, N., Coppieters, K. T. & von Herrath, M. G. The
 864 healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in
 865 type 1 diabetes. *Sci. Adv.* 6, eabc5586 (2020).
- 866 23. Fasolino, M. *et al.* Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes. *Nat. Metab.* 4, 284–299 (2022).
- 868 24. Korpos, É. *et al.* The Peri-islet Basement Membrane, a Barrier to Infiltrating Leukocytes in
 869 Type 1 Diabetes in Mouse and Human. *Diabetes* 62, 531–542 (2013).
- 870 25. Savinov, A. Y., Wong, F. S., Stonebraker, A. C. & Chervonsky, A. V. Presentation of
 871 Antigen by Endothelial Cells and Chemoattraction Are Required for Homing of Insulin872 specific CD8+ T Cells. J. Exp. Med. 197, 643–656 (2003).
- 873 26. In't Veld, P. Insulitis in human type 1 diabetes: a comparison between patients and animal
 874 models. *Semin. Immunopathol.* 36, 569–579 (2014).
- 875 27. In't Veld, P. Insulitis in human type 1 diabetes: The quest for an elusive lesion. *Islets* 3, 131–
 876 138 (2011).
- 877 28. Atkinson, M. A. & Mirmira, R. G. The pathogenic "symphony" in type 1 diabetes: A
 878 disorder of the immune system, β cells, and exocrine pancreas. *Cell Metab.* 35, 1500–1518
 879 (2023).
- 880 29. Bruggeman, B. S. *et al.* Substance Use Affects Type 1 Diabetes Pancreas Pathology:
 881 Implications for Future Studies. *Front. Endocrinol.* 12, (2021).
- 30. Schürch, C. M. *et al.* Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. *Cell* 183, 838 (2020).
- 884 31. Phillips, D. *et al.* Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. *Nat. Commun.* 12, 6726 (2021).
- 32. Hickey, J. W., Tan, Y., Nolan, G. P. & Goltsev, Y. Strategies for Accurate Cell Type
 Identification in CODEX Multiplexed Imaging Data. *Front. Immunol.* 12, (2021).
- 33. Lee, M. Y. *et al.* CellSeg: a robust, pre-trained nucleus segmentation and pixel quantification
 software for highly multiplexed fluorescence images. *BMC Bioinformatics* 23, 46 (2022).
- 34. Dalmas, E. *et al.* Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote
 Insulin Secretion through Myeloid Cell Retinoic Acid Production. *Immunity* 47, 928-942.e7
 (2017).
- 893 35. Campbell-Thompson, M. *et al.* Insulitis and β-Cell Mass in the Natural History of Type 1
 894 Diabetes. *Diabetes* 65, 719–731 (2016).
- 895 36. Richardson, S. J. & Pugliese, A. 100 YEARS OF INSULIN: Pancreas pathology in type 1
 896 diabetes: an evolving story. *J. Endocrinol.* 252, R41–R57 (2022).
- 897 37. Wolf, F. A. *et al.* PAGA: graph abstraction reconciles clustering with trajectory inference
 898 through a topology preserving map of single cells. *Genome Biol.* 20, 59 (2019).
- 38. Saelens, W., Cannoodt, R., Todorov, H. & Saeys, Y. A comparison of single-cell trajectory
 inference methods. *Nat. Biotechnol.* 37, 547–554 (2019).

- 39. Munn, D. H. & Mellor, A. L. IDO in the Tumor Microenvironment: Inflammation, Counter Regulation, and Tolerance. *Trends Immunol.* 37, 193–207 (2016).
- 40. Diggins, K. E. *et al.* Exhausted-like CD8⁺ T cell phenotypes linked to C-peptide preservation
 in alefacept-treated T1D subjects. *JCI Insight* 6, (2021).
- 41. Gepts, W. Pathologic Anatomy of the Pancreas in Juvenile Diabetes Mellitus. *Diabetes* 14, 619–633 (1965).
- 42. Gelman, A. *et al.* Bayesian Data Analysis Third edition (with errors fixed as of 15 February 2021). 677.
- 43. Jerby-Arnon, L. & Regev, A. DIALOGUE maps multicellular programs in tissue from
 single-cell or spatial transcriptomics data. *Nat. Biotechnol.* 40, 1467–1477 (2022).
- 44. Yi, N., Tang, Z., Zhang, X. & Guo, B. BhGLM: Bayesian hierarchical GLMs and survival
 models, with applications to genomics and epidemiology. *Bioinformatics* 35, 1419–1421
 (2019).
- 45. Bhate, S. S., Barlow, G. L., Schürch, C. M. & Nolan, G. P. Tissue schematics map the
 specialization of immune tissue motifs and their appropriation by tumors. *Cell Syst.* (2021)
 doi:10.1016/j.cels.2021.09.012.
- 46. Agrawal, S. M. *et al.* Extracellular matrix metalloproteinase inducer shows active
 perivascular cuffs in multiple sclerosis. *Brain* 136, 1760–1777 (2013).
- 919 47. Wekerle, H. B cells in multiple sclerosis. *Autoimmunity* **50**, 57–60 (2017).
- 48. Rovituso, D. M. *et al.* CEACAM1 mediates B cell aggregation in central nervous system
 autoimmunity. *Sci. Rep.* 6, 29847 (2016).
- 49. Alexander, A. M. *et al.* Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD
 Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes: *Diabetes* 51, 356–365 (2002).
- 50. Yoshihara, E. *et al.* Immune-evasive human islet-like organoids ameliorate diabetes. *Nature*586, 606–611 (2020).
- 51. Castro-Gutierrez, R., Alkanani, A., Mathews, C. E., Michels, A. & Russ, H. A. Protecting
 Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic T Cell Recognition. *Front. Endocrinol.* 12, (2021).
- 930 52. Anquetil, F. *et al.* Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their
 931 Destruction During the Development of Type 1 Diabetes. *Diabetes* 67, 1858–1866 (2018).
- 53. Sarkar, S. A. *et al.* Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. *Diabetes* 56, 72–79 (2007).
- 54. Christoffersson, G., Ratliff, S. S. & von Herrath, M. G. Interference with pancreatic
 sympathetic signaling halts the onset of diabetes in mice. *Sci. Adv.* 6, eabb2878 (2020).
- 55. Penaranda, C., Tang, Q., Ruddle, N. H. & Bluestone, J. A. Prevention of Diabetes by
 FTY720-Mediated Stabilization of Peri-Islet Tertiary Lymphoid Organs. *Diabetes* 59, 1461–
 1468 (2010).
- 56. In't Veld, P. *et al.* Beta-cell replication is increased in donor organs from young patients
 after prolonged life support. *Diabetes* 59, 1702–1708 (2010).
- 57. Ziegler, A. G. *et al.* Seroconversion to Multiple Islet Autoantibodies and Risk of Progression
 to Diabetes in Children. *JAMA* 309, 2473–2479 (2013).
- 58. Kennedy-Darling, J. *et al.* Highly multiplexed tissue imaging using repeated oligonucleotide
 exchange reaction. *Eur. J. Immunol.* 51, 1262–1277 (2021).
- 59. Black, S. *et al.* CODEX multiplexed tissue imaging with DNA-conjugated antibodies. *Nat. Protoc.* 16, 3802–3835 (2021).

- 60. Phillips, D. *et al.* Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the
 Tumor Microenvironment by CODEX Tissue Imaging. *Front. Immunol.* 12, 687673 (2021).
- 61. Goltsev, Y. *et al.* Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed
 Imaging. *Cell* 174, 968-981.e15 (2018).
- 62. Sainburg, T., McInnes, L. & Gentner, T. Q. Parametric UMAP embeddings for representation and semi-supervised learning. Preprint at
- 953 https://doi.org/10.48550/arXiv.2009.12981 (2021).
- 63. Abhishek Dutta & Andrew Zisserman. The VIA Annotation Software for Images, Audio and
 Video. in (ACM, Nice, France, 2019). doi:10.1145/3343031.3350535.
- 956 64. Shekarian, T. *et al.* Immunotherapy of glioblastoma explants induces interferon-γ responses
 957 and spatial immune cell rearrangements in tumor center, but not periphery.
- 958 2022.01.19.474897 Preprint at https://doi.org/10.1101/2022.01.19.474897 (2022).
- 65. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models Using
 lme4. J. Stat. Softw. 67, 1–48 (2015).
- 66. Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. ImerTest Package: Tests in Linear
 Mixed Effects Models. J. Stat. Softw. 82, 1–26 (2017).
- 963 964

965 Acknowledgements

966 This research was performed with the support of the Network for Pancreatic Organ donors with Diabetes (nPOD; RRID:SCR 014641), a collaborative type 1 diabetes research project supported 967 968 by JDRF (nPOD: 5-SRA-2018-557-Q-R) and The Leona M. & Harry B. Helmsley Charitable Trust 969 (Grant#2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility 970 of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement 971 Organizations (OPO) partnering with nPOD to provide research resources are listed 972 at http://www.jdrfnpod.org/for-partners/npod-partners/. Research reported in this publication 973 was supported by the National Cancer Institute and National Institute of Allergy and Infectious 974 Diseases of the National Institutes of Health under Award Numbers K99CA246061, 975 5U54CA209971-05, 5U2CCA233195-02, 1U2CCA233238-01, 5U2CCA233195-02, 5U01AI101984-09. The 976 content is solely the responsibility of the authors and does not necessarily represent the official 977 views of the National Institutes of Health, C.M.S. was supported by the Swiss National Science 978 Foundation (P300PB 171189, P400PM 183915). We like to thank Yury Goltsev, Pauline Chu, 979 Sarah Black, Gustavo Vazquez, Aviv Hargil (Stanford University), and Irina Kusmartseva (nPOD) 980 for excellent assistance. We like to thank Dr. Xavier Rovira-Clavé (Stanford University) for critical 981 comments on the manuscript.

982 Author information

G.L.B curated data, wrote software, and analyzed data. D.P. and C.M.S contributed significantly
to validating the antibody panel and assisted with analysis. S.D., S.S.B, A.Y., H.A.M., G.K.K., N.N.,
S.R., and J.M. assisted with analysis. G.L.B., J.A.B., G.P.N., and P.L.B., conceptualized the study
and wrote the manuscript. All authors have read and approved the final version of the
manuscript.

988 Ethics declarations

- 989 P.L.B.: Founder, Halo Biosciences.
- 990 N.N.: Founder, Halo Biosciences.
- PLB, NN and GK have filed intellectual property around 4-MU. PLB, NN and GK hold a financialinterest in Halo Biosciences, a company that is developing 4-MU for various indications.
- 993 G.P.N. has received research grants from Vaxart and Celgene during the course of this work and
- has equity in and is a scientific advisory board member of Akoya Biosciences. Akoya Biosciences
- makes reagents and instruments that are dependent on licenses from Stanford University.Stanford University has been granted US patent 9909167, which covers some aspects of the
- 997 technology described in this paper.
- J.A.B.: Board of director for Gilead and CEO and President of Sonoma Biotherapeutics; scientific
 advisory boards of Arcus Biotherapeutics and Cimeio Therapeutics; consultant for Rheos
 Medicines, Provention Bio; stockholder in Rheos Medicines, Vir Therapeutics, Arcus
 Biotherapeutics, Solid Biosciences, Celsius Therapeutics; Gilead Sciences, Provention Bio,
- 1002 Sonoma Biotherapeutics.
- 1003 C.M.S.: Scientific advisory board of, stock options in, research funding from Enable Medicine, Inc.